Vitamin K status in chronic kidney disease

Kristin M McCabe, Michael A Adams, Rachel M Holden, Kristin M McCabe, Michael A Adams, Rachel M Holden

Abstract

The purpose of this review is to summarize the research to date on vitamin K status in chronic kidney disease (CKD). This review includes a summary of the data available on vitamin K status in patients across the spectrum of CKD as well as the link between vitamin K deficiency in CKD and bone dynamics, including mineralization and demineralization, as well as ectopic mineralization. It also describes two current clinical trials that are underway evaluating vitamin K treatment in CKD patients. These data may inform future clinical practice in this population.

References

    1. Coresh J., Selvin E., Stevens L.A., Manzi J., Kusek J.W., Eggers P., van Lente F., Levey A.S. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–2047. doi: 10.1001/jama.298.17.2038.
    1. Levin A., Hemmelgarn B., Culleton B., Tobe S., McFarlane P., Ruzicka M., Burns K., Manns B., White C., Madore F., et al. Guidelines for the management of chronic kidney disease. Can. Med. Assoc. J. 2008;179:1154–1162. doi: 10.1503/cmaj.080351.
    1. Pilkey R.M., Morton A.R., Boffa M.B., Noordhof C., Day A.G., Su Y., Miller L.M., Koschinsky M.L., Booth S.L. Subclinical vitamin K deficiency in hemodialysis patients. Am. J. Kidney Dis. 2007;49:432–439. doi: 10.1053/j.ajkd.2006.11.041.
    1. Kohlmeier M., Saupe J., Shearer M.J., Schaefer K., Asmus G. Bone health of adult hemodialysis patients is related to vitamin K status. Kidney Int. 1997;51:1218–1221. doi: 10.1038/ki.1997.166.
    1. Westenfeld R., Krueger T., Schlieper G., Cranenburg E.C., Magdeleyns E.J., Heidenreich S., Holzmann S., Vermeer C., Jahnen-Dechent W., Ketteler M., et al. Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: A randomized trial. Am. J. Kidney Dis. 2012;59:186–195. doi: 10.1053/j.ajkd.2011.10.041.
    1. Cranenburg E.C., Schurgers L.J., Uiterwijk H.H., Beulens J.W., Dalmeijer G.W., Westerhuis R., Magdeleyns E.J., Herfs M., Vermeer C., Laverman G.D. Vitamin K intake and status are low in hemodialysis patients. Kidney Int. 2012;82:605–610. doi: 10.1038/ki.2012.191.
    1. Booth S.L., Al Rajabi A. Determinants of vitamin K status in humans. Vitaminesand Hormones. 2008;78:1–22. doi: 10.1016/S0083-6729(07)00001-5.
    1. Thijssen H.H., Drittij-Reijnders M.J. Vitamin K distribution in rat tissues: Dietary phylloquinone is a source of tissue menaquinone-4. Br. J. Nutr. 1994;72:415–425. doi: 10.1079/BJN19940043.
    1. McCabe K., Booth S., Fu X., Shobeiri N., Pang J., Adams M., Holden R. Dietary vitamin K and therapeutic warfarin alter the susceptibility to vascular calcification in experimental chronic kidney disease. Kidney Int. 2013;83:835–844. doi: 10.1038/ki.2012.477.
    1. Krueger T., Westenfeld R., Ketteler M., Schurgers L.J., Floege J. Vitamin K deficiency in ckd patients: a modifiable risk factor for vascular calcification? Kidney Int. 2009;76:18–22. doi: 10.1038/ki.2009.126.
    1. Schurgers L.J., Barreto D.V., Barreto F.C., Liabeuf S., Renard C., Magdeleyns E.J., Vermeer C., Choukroun G., Massy Z.A. The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: A preliminary report. Clin. J. Am. Soc. Nephrol. 2010;5:568–575. doi: 10.2215/CJN.07081009.
    1. Price P.A., Faus S.A., Williamson M.K. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler. Thromb. Vasc. Biol. 1998;18:1400–1407. doi: 10.1161/01.ATV.18.9.1400.
    1. Schurgers L.J., Spronk H.M., Soute B.A., Schiffers P.M., DeMey J.G., Vermeer C. Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats. Blood. 2007;109:2823–2831.
    1. Spronk H.M., Soute B.A., Schurgers L.J., Thijssen H.H., De Mey J.G., Vermeer C. Tissue-specific utilization of menaquinone-4 results in the prevention of arterial calcification in warfarin-treated rats. J. Vasc. Res. 2003;40:531–537. doi: 10.1159/000075344.
    1. Holden R.M., Morton A.R., Garland J.S., Pavlov A., Day A.G., Booth S.L. Vitamins K and D status in stages 3–5 chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2010;5:590–597. doi: 10.2215/CJN.06420909.
    1. Kohlmeier M., Saupe J., Drossel H.J., Shearer M.J. Variation of Phylloquinone (Vitamin K1) concentrations in hemodialysis patients. Thromb. Haemostasis. 1995;74:1252–1254.
    1. Schlieper G., Westenfeld R., Kruger T., Cranenburg E.C., Magdeleyns E.J., Brandenburg V.M., Djuric Z., Damjanovic T., Ketteler M., Vermeer C., et al. Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. J. Am. Soc. Nephrol. 2011;22:387–395. doi: 10.1681/ASN.2010040339.
    1. Stankowiak-Kulpa H., Krzyzanowska P., Koziol L., Grzymislawski M., Wanic-Kossowska M., Moczko J., Walkowiak J. Vitamin K status in peritoneally dialyzed patients with chronic kidney disease. Acta Biochim. Pol. 2011;58:617–620.
    1. Holden R.M., Iliescu E., Morton A.R., Booth S.L. Vitamin K status of canadian peritoneal dialysis patients. Perit. Dial. Int. 2008;28:415–418.
    1. Fusaro M., Crepaldi G., Maggi S., Galli F., D’Angelo A., Calo L., Giannini S., Miozzo D., Gallieni M. Vitamin K, bone fractures, and vascular calcifications in chronic kidney disease: An important but poorly studied relationship. J. Endocrinol. Investig. 2011;34:317–323.
    1. Jadoul M., Albert J.M., Akiba T., Akizawa T., Arab L., Bragg-Gresham J.L., Mason N., Prutz K.G., Young E.W., Pisoni R.L. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the dialysis outcomes and practice patterns study. Kidney Int. 2006;70:1358–1366. doi: 10.1038/sj.ki.5001754.
    1. Fusaro M., Noale M., Viola V., Galli F., Tripepi G., Vajente N., Plebani M., Zaninotto M., Guglielmi G., Miotto D., et al. VItamin K Italian (VIKI) dialysis study investigators. Vitamin K, vertebral fractures, vascular calcifications, and mortality: Vitamin K Italian (VIKI) dialysis study. J. Bone Miner. Res. 2012;27:2271–2278. doi: 10.1002/jbmr.1677.
    1. Reichel H. No effect of vitamin k1 supplementation on biochemical bone markers in haemodialysis patients. Nephrol. Dial. Transpl. 1999;14:249–250. doi: 10.1093/ndt/14.1.249b.
    1. Sugimoto T., Yamakado M., Matsushita K., Iwamoto T., Tagawa H. Pharmacodynamics of menatetrenone and effects on bone metabolism in continuous ambulatory peritoneal dialysis patients. J. Int. Med. Res. 2002;30:566–575. doi: 10.1177/147323000203000604.
    1. Fusaro M., Tripepi G., Noale M., Plebani M., Zaninotto M., Piccoli A., Naso A., Miozzo D., Giannini S., Avolio M., et al. Prevalence of vertebral fractures, vascular calcifications, and mortality in warfarin treated hemodialysis patients. Curr. Vasc. Pharmacol. 2013 in press.
    1. Detrano R., Guerci A.D., Carr J.J., Bild D.E., Burke G., Folsom A.R., Liu K., Shea S., Szklo M., Bluemke D.A., et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N. Engl. J. Med. 2008;358:1336–1345. doi: 10.1056/NEJMoa072100.
    1. Thompson G.R., Partridge J. Coronary calcification score: The coronary-risk impact factor. Lancet. 2004;363:557–559. doi: 10.1016/S0140-6736(04)15544-X.
    1. Vliegenthart R., Oudkerk M., Hofman A., Oei H.H., van Dijck W., van Rooij F.J., Witteman J.C. Coronary calcification improves cardiovascular risk prediction in the elderly. Circulation. 2005;112:572–577. doi: 10.1161/CIRCULATIONAHA.104.488916.
    1. Coylewright M., Rice K., Budoff M.J., Blumenthal R.S., Greenland P., Kronmal R., Barr R.G., Burke G.L., Tracy R., Post W.S. Differentiation of severe coronary artery calcification in the multi-ethnic study of atherosclerosis. Atherosclerosis. 2011;219:616–622. doi: 10.1016/j.atherosclerosis.2011.08.038.
    1. Qunibi W.Y. Reducing the burden of cardiovascular calcification in patients with chronic kidney disease. J. Am. Soc. Nephrol. 2005;16:S95–S102. doi: 10.1681/ASN.2005060666.
    1. Goodman W.G., Goldin J., Kuizon B.D., Yoon C., Gales B., Sider D., Wang Y., Chung J., Emerick A., Greaser L., et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med. 2000;342:1478–1483. doi: 10.1056/NEJM200005183422003.
    1. Cranenburg E.C., Brandenburg V.M., Vermeer C., Stenger M., Muhlenbruch G., Mahnken A.H., Gladziwa U., Ketteler M., Schurgers L.J. Uncarboxylated matrix gla protein (ucMGP) is associated with coronary artery calcification in haemodialysis patients. Thromb. Haemostasis. 2009;101:359–366.
    1. Schurgers L.J., Spronk H.M., Skepper J.N., Hackeng T.M., Shanahan C.M., Vermeer C., Weissberg P.L., Proudfoot D. Post-translational modifications regulate matrix gla protein function: Importance for inhibition of vascular smooth muscle cell calcification. J. Thromb. Haemost. 2007;5:2503–2511. doi: 10.1111/j.1538-7836.2007.02758.x.
    1. Holden R.M., Sanfilippo A.S., Hopman W.M., Zimmerman D., Garland J.S., Morton A.R. Warfarin and aortic valve calcification in hemodialysis patients. J. Nephrol. 2007;20:417–422.
    1. Wizemann V., Tong L., Satayathum S., Disney A., Akiba T., Fissell R.B., Kerr P.G., Young E.W., Robinson B.M. Atrial fibrillation in hemodialysis patients: Clinical features and associations with anticoagulant therapy. Kidney Int. 2010;77:1098–1106. doi: 10.1038/ki.2009.477.
    1. Shea M.K., O’Donnell C.J., Hoffmann U., Dallal G.E., Dawson-Hughes B., Ordovas J.M., Price P.A., Williamson M.K., Booth S.L. Vitamin K supplementation and progression of coronary artery calcium in older men and women. Am. J. Clin. Nutr. 2009;89:1799–1807. doi: 10.3945/ajcn.2008.27338.
    1. Braam L.A., Hoeks A.P., Brouns F., Hamulyak K., Gerichhausen M.J., Vermeer C. Beneficial effects of vitamins D and K on the elastic properties of the vessel wall in postmenopausal women: A follow-up study. Thromb. Haemostasis. 2004;91:373–380.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する